Literature DB >> 11844900

Downregulation of striatal dopamine D2 receptors in advanced Parkinson's disease contributes to the development of motor fluctuation.

Wen-Jun Hwang1, Wei-Jen Yao, Shiaw-Pyng Wey, Lie-Hang Shen, Gann Ting.   

Abstract

The purpose of this study was to evaluate the contribution of the postsynaptic mechanism to the development of motor fluctuation in advanced Parkinson's disease (PD). We used 123I-iodobenzamide single-photon emission computed tomography to measure the striatal dopamine D2 receptor densities in early levodopa-naïve PD, chronic PD with stable levodopa response, and advanced PD with fluctuating levodopa response. The basal ganglia/frontal cortex ratios at both hemispheres were calculated and averaged. PD patients with fluctuating levodopa response showed a significant decrease in striatal dopamine D2 receptor densities compared to those with early (1.57+/- 0.20 vs. 1.77 +/- 0.12, p = 0.009) or chronic stable PD (1.57 +/- 0.20 vs. 1.77 +/- 0.10, p = 0.024). We conclude that the decreased D2 receptor densities in advanced PD reduced the 'safety factor' for synaptic transmission and contributed to the development of motor fluctuation. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11844900     DOI: 10.1159/000047962

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  7 in total

Review 1.  Brain SPECT imaging in multiple system atrophy.

Authors:  R Cilia; G Marotta; R Benti; G Pezzoli; A Antonini
Journal:  J Neural Transm (Vienna)       Date:  2005-12       Impact factor: 3.575

Review 2.  Neurophysiology and neurochemistry of corticobasal syndrome.

Authors:  Aditya A Murgai; Mandar S Jog
Journal:  J Neurol       Date:  2018-01-06       Impact factor: 4.849

3.  Effect of PD I administration on dopamine receptors mRNAs expression in the lesioned striatum of PD rat model.

Authors:  Yang Mei; Shenggang Sun; Xuebing Cao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2005

4.  IBZM tool: a fully automated expert system for the evaluation of IBZM SPECT studies.

Authors:  Ralph Buchert; Georg Berding; Florian Wilke; Brigitte Martin; Daniel von Borczyskowski; Janos Mester; Winfried Brenner; Malte Clausen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-04-14       Impact factor: 9.236

5.  Binding of the Dual-Action Anti-Parkinsonian Drug AG-0029 to Dopamine D2 and Histamine H3 Receptors: A PET Study in Healthy Rats.

Authors:  Nafiseh Ghazanfari; Aren van Waarde; Janine Doorduin; Jürgen W A Sijbesma; Maria Kominia; Martin Koelewijn; Khaled Attia; David Vállez-García; Antoon T M Willemsen; André Heeres; Rudi A J O Dierckx; Ton J Visser; Erik F J de Vries; Philip H Elsinga
Journal:  Mol Pharm       Date:  2022-06-22       Impact factor: 5.364

6.  Possible impact of dopamine SPECT on decision-making for drug treatment in Parkinsonian syndrome.

Authors:  S Hesse; C Oehlwein; H Barthel; J Schwarz; D Polster; A Wagner; O Sabri
Journal:  J Neural Transm (Vienna)       Date:  2006-02-06       Impact factor: 3.575

Review 7.  SPECT molecular imaging in Parkinson's disease.

Authors:  Ling Wang; Qi Zhang; Huanbin Li; Hong Zhang
Journal:  J Biomed Biotechnol       Date:  2012-03-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.